|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2004-11-2
|
|
pubmed:abstractText |
Once-weekly dosing of recombinant human erythropoietin (rhEPO) in patients with myelodysplastic syndromes (MDS) has not been investigated thoroughly. We performed a clinical trial to evaluate the effects of this new dosing regimen in patients with MDS who were unresponsive to the conventional three-times-weekly schedule.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1684-90
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15520072-Aged,
pubmed-meshheading:15520072-Aged, 80 and over,
pubmed-meshheading:15520072-Antigens, CD34,
pubmed-meshheading:15520072-Apoptosis,
pubmed-meshheading:15520072-Dose-Response Relationship, Drug,
pubmed-meshheading:15520072-Drug Administration Schedule,
pubmed-meshheading:15520072-Erythropoietin,
pubmed-meshheading:15520072-Female,
pubmed-meshheading:15520072-Flow Cytometry,
pubmed-meshheading:15520072-Humans,
pubmed-meshheading:15520072-Male,
pubmed-meshheading:15520072-Middle Aged,
pubmed-meshheading:15520072-Myelodysplastic Syndromes,
pubmed-meshheading:15520072-Prognosis,
pubmed-meshheading:15520072-Recombinant Proteins,
pubmed-meshheading:15520072-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing.
|
|
pubmed:affiliation |
Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy. roberto.stasi@uniroma2.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
